LCTX
Lineage Cell Therapeutics Inc
NYSE MKT: LCTX · HEALTHCARE · BIOTECHNOLOGY
$1.43
-2.05% today
Updated 2026-05-06
Market cap
$363.98M
P/E ratio
—
P/S ratio
25.01x
EPS (TTM)
$-0.28
Dividend yield
—
52W range
$0 – $2
Volume
1.2M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+6.5
Quality
B2.5
Profitability
F5.7
Valuation
C+3/9
Piotroski F-Score
Weak
-3.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$5.14
+259.44%
12-Month target
—
—
Intrinsic (DCF)
$13.55
Margin of safety
+86.72%
1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 130.40% QoQ
+ 86.72% below intrinsic value
+ Debt/equity 0.12x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -3.83 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.99M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $14.70M | $8.95M | $9.50M | $14.56M | $14.56M |
| Net income | $-26.27M | $-21.49M | $-18.61M | $-63.53M | $851000.00 |
| EPS | — | — | — | — | $-0.28 |
| Free cash flow | $646000.00 | $-29.24M | $-23.66M | $-19.44M | $-4.99M |
| Profit margin | -178.69% | -240.20% | -195.90% | -436.47% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-12 | CULLEY, BRIAN M | Buy | 15,000 | $1.63 |
| 2026-03-05 | SAMUEL, GEORGE A. III | Buy | 900,000 | — |
| 2026-03-05 | HOWE, JILL ANN | Buy | 1,050,000 | — |
Peer comparison
Smart narrative
Lineage Cell Therapeutics Inc trades at $1.43. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -3.83, it sits in the distress. TTM revenue stands at $14.56M. Our DCF model estimates intrinsic value at $13.55.
Frequently asked questions
What is Lineage Cell Therapeutics Inc's stock price?
Lineage Cell Therapeutics Inc (LCTX) trades at $1.43.
Is Lineage Cell Therapeutics Inc overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell). DCF value $13.55.
What is the price target of Lineage Cell Therapeutics Inc (LCTX)?
The analyst target price is $5.14, representing +259.4% upside from the current price of $1.43.
What is the intrinsic value of Lineage Cell Therapeutics Inc (LCTX)?
Based on our DCF model, intrinsic value is $13.55, a +86.7% margin of safety versus $1.43.
What is Lineage Cell Therapeutics Inc's revenue?
TTM revenue is $14.56M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-3.83 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE MKT
CurrencyUSD
Quick metrics
P/S ratio25.01x
ROE-105.30%
Beta1.60
50D MA$1.63
200D MA$1.57
Shares out0.25B
Float0.19B
Short ratio—
Avg volume1.2M
Performance
1 week+0.00%
1 month+10.81%
3 months-0.61%
YTD-1.80%
1 year—
3 years—
5 years—